Marco Bandini1,2, Michele Marchioni2,3, Raisa S Pompe2,4, Zhe Tian2, Tristan Martel2, Felix K Chun4, Luca Cindolo5, Anil Kapoor6, Francesco Montorsi1, Shahrokh F Shariat7, Alberto Briganti1, Pierre I Karakiewicz2. 1. Division of Oncology/Unit of Urology, URI, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy. 2. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, QC, Canada. 3. Department of Urology, SS Annunziata Hospital, G. D'Annunzio University of Chieti, Chieti, Italy. 4. Martini-Klinik Prostate Cancer Centre, University Hospital Hamburg-Eppendorf, Hamburg, Germany. 5. Department of Urology, ASL Abruzzo 2, Chieti, Italy. 6. Division of Urology, McMaster University, Hamilton, ON, Canada. 7. Department of Urology, Medical University of Vienna, Vienna, Austria.
Abstract
INTRODUCTION: Contemporary data regarding the effect of age, especially in elderly patients, on cancer-specific mortality (CSM) for pT1a renal cell carcinoma (RCC) are lacking. The objective of the current study is to evaluate CSM in a large population-based cohort of surgically treated pT1a RCC patients according to age groups. METHODS: Within the Surveillance Epidemiology and End Results database (2000-2013), we identified 37 121 pT1a RCC patients who underwent either partial or radical nephrectomy. The population was stratified into five groups according to decades: <50, 50-59, 60-69, 70-79, and ≥80 years. The effect of age on CSM was evaluated using competing risks regression models according to Fuhrman grade (FG). Analyses were repeated in clear-cell RCC (ccRCC). RESULTS: Patients aged 50-59 (9615), 60-69 (10 762), 70-79 (7096), and ≥80 (1789) years demonstrated higher rate of CSM compared to patients aged <50 (7856) years (hazard ratios [HR] 2.11, 3.04, 4.47, and 7.56, respectively; all p<0.001). The effect of age on CSM in FG 1-2 patients resulted in HRs ranging from 2.01-8.23 for the same age decades (all p< 0.001). Similarly, the effect of age on CSM in FG 3-4 patients resulted in HRs ranging from 2.38-5.92, respectively (all p<0.001). Virtually the same results were recorded in ccRCC patients. CONCLUSIONS: Older age is associated with higher CSM in surgically treated patients with pT1a RCC. This effect seems to be more pronounced in patient with FG 1-2 disease. This observation should be considered when making treatment decisions in elderly patients.
INTRODUCTION: Contemporary data regarding the effect of age, especially in elderly patients, on cancer-specific mortality (CSM) for pT1a renal cell carcinoma (RCC) are lacking. The objective of the current study is to evaluate CSM in a large population-based cohort of surgically treated pT1a RCCpatients according to age groups. METHODS: Within the Surveillance Epidemiology and End Results database (2000-2013), we identified 37 121 pT1a RCCpatients who underwent either partial or radical nephrectomy. The population was stratified into five groups according to decades: <50, 50-59, 60-69, 70-79, and ≥80 years. The effect of age on CSM was evaluated using competing risks regression models according to Fuhrman grade (FG). Analyses were repeated in clear-cell RCC (ccRCC). RESULTS:Patients aged 50-59 (9615), 60-69 (10 762), 70-79 (7096), and ≥80 (1789) years demonstrated higher rate of CSM compared to patients aged <50 (7856) years (hazard ratios [HR] 2.11, 3.04, 4.47, and 7.56, respectively; all p<0.001). The effect of age on CSM in FG 1-2 patients resulted in HRs ranging from 2.01-8.23 for the same age decades (all p< 0.001). Similarly, the effect of age on CSM in FG 3-4 patients resulted in HRs ranging from 2.38-5.92, respectively (all p<0.001). Virtually the same results were recorded in ccRCC patients. CONCLUSIONS: Older age is associated with higher CSM in surgically treated patients with pT1a RCC. This effect seems to be more pronounced in patient with FG 1-2 disease. This observation should be considered when making treatment decisions in elderly patients.
Authors: Hong Truong; Sarah E Hegarty; Leonard G Gomella; William K Kelly; Edouard J Trabulsi; Costas D Lallas; Veda N Giri Journal: J Genet Couns Date: 2017-01-19 Impact factor: 2.537
Authors: Christopher J Kane; Katherine Mallin; Jamie Ritchey; Matthew R Cooperberg; Peter R Carroll Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: Thiago Camelo Mourão; Diego Abreu; Gustavo F Carvalhal; Guillermo Gueglio; Walter H da Costa; Vinicius Fernando Calsavara; Luis Meza-Montoya; Rubén G Bengió; Carlos Scorticati; Ricardo Castillejos-Molina; Francisco Rodríguez-Covarrubias; Ana María Autran-Gómez; José Gadu Campos-Salcedo; Alejandro Nolazco; Carlos Ameri; Hamilton Zampolli; Raúl Langenhin; Diego Muguruza; Marcos Tobias Machado; Pablo Mingote; Jorge Clavijo; Lucas Nogueira; Omar Clark; Agustín R Rovegno; Fernando P Secin; Ricardo Decia; Gustavo C Guimarães; Sidney Glina; Oscar Rodríguez-Faba; Joan Palou; Stenio C Zequi Journal: BMC Urol Date: 2020-07-02 Impact factor: 2.264
Authors: Ken Batai; Alfredo Harb-De la Rosa; Jiping Zeng; Juan J Chipollini; Francine C Gachupin; Benjamin R Lee Journal: Cancer Med Date: 2019-09-11 Impact factor: 4.452